Follistatin Alleviates Hepatic Steatosis in NAFLD via the mTOR Dependent Pathway

Regulation and metabolic functions of mTORC1 and mTORC2

(2021) Angelia Szwed et al.   PHYSIOLOGICAL REVIEWS

Non-alcoholic fatty liver disease

(2021) Elizabeth E Powell et al.   LANCET

Follistatin Attenuates Myocardial Fibrosis in Diabetic Cardiomyopathy via the TGF-β–Smad3 Pathway

(2021) Yinhui Wang et al.   Frontiers in Pharmacology

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease

(2021) Chander K. Negi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Elevated circulating follistatin associates with an increased risk of type 2 diabetes

(2021) Chuanyan Wu et al.   Nature Communications

Follistatin is a novel therapeutic target and biomarker in FLT 3/ ITD acute myeloid leukemia

(2020) Bai‐Liang He et al.   EMBO Molecular Medicine

Circulating follistatin and activin A and their regulation by insulin in obesity and type 2 diabetes

(2020) Lykke Sylow et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Update on NAFLD genetics: from new variants to the clinic

(2020) Eric Trépo et al.   JOURNAL OF HEPATOLOGY

mTOR at the nexus of nutrition, growth, ageing and disease

(2020) Grace Y. Liu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

(2020) Jean-François Dufour et al.   GUT

Nonalcoholic Steatohepatitis

(2020) Adam C. Sheka et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

(2020) Mohammed Eslam et al.   JOURNAL OF HEPATOLOGY

Tracing insights into de novo lipogenesis in liver and adipose tissues

(2020) Martina Wallace et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat diet–induced obesity

(2020) Ruhang Tang et al.   Science Advances

The liver as an endocrine organ - linking NAFLD and insulin resistance

(2019) Matthew J Watt et al.   ENDOCRINE REVIEWS

Past, present and future perspectives in nonalcoholic fatty liver disease

(2019) Arun J. Sanyal   Nature Reviews Gastroenterology & Hepatology

Intraperitoneal administration of follistatin promotes adipocyte browning in high-fat diet-induced obese mice

(2019) Haoyu Li et al.   PLoS One

Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease

(2018) David Højland Ipsen et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

(2018) Zobair M. Younossi et al.   HEPATOLOGY

Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice

(2018) Albert G. Linden et al.   JOURNAL OF LIPID RESEARCH

Inactivating hepatic follistatin alleviates hyperglycemia

(2018) Rongya Tao et al.   NATURE MEDICINE

Mechanisms of NAFLD development and therapeutic strategies

(2018) Scott L. Friedman et al.   NATURE MEDICINE

Modulation of Insulin Resistance in NAFLD

(2018) Reenam Khan et al.   HEPATOLOGY

Non-alcoholic fatty liver disease – A global public health perspective

(2018) Zobair M. Younossi   JOURNAL OF HEPATOLOGY

mTOR as a central hub of nutrient signalling and cell growth

(2018) Joungmok Kim et al.   NATURE CELL BIOLOGY

Current and future pharmacological therapies for NAFLD/NASH

(2017) Yoshio Sumida et al.   JOURNAL OF GASTROENTEROLOGY

Activin and follistatin interactions in the male reproductive tract: activin expression and morphological abnormalities in mice lacking follistatin 288

(2017) R. Wijayarathna et al.   Andrology

Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease

(2016) Samir Softic et al.   DIGESTIVE DISEASES AND SCIENCES

Activin A and follistatin in patients with nonalcoholic fatty liver disease

(2016) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Circulating follistatin in relation to energy metabolism

(2016) Jakob Schiøler Hansen et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

The Roles of mTOR Complexes in Lipid Metabolism

(2015) Alexandre Caron et al.   Annual Review of Nutrition

De novolipogenesis in the liver in health and disease: more than just a shunting yard for glucose

(2015) Francis W. B. Sanders et al.   BIOLOGICAL REVIEWS

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

(2015) Eduardo Vilar-Gomez et al.   GASTROENTEROLOGY

Nonalcoholic Fatty Liver Disease

(2015) Mary E. Rinella   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

NAFLD: A multisystem disease

(2015) Christopher D. Byrne et al.   JOURNAL OF HEPATOLOGY

Follistatin promotes adipocyte differentiation, browning, and energy metabolism

(2014) Melissa Braga et al.   JOURNAL OF LIPID RESEARCH

Inhibition of the mTOR pathway: A possible protective role in coronary artery disease

(2013) Giovanni Tarantino et al.   ANNALS OF MEDICINE

A Central Role for mTOR in Lipid Homeostasis

(2013) Dudley W. Lamming et al.   Cell Metabolism

Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation

(2013) J. Hansen et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Exercise Induces a Marked Increase in Plasma Follistatin: Evidence That Follistatin Is a Contraction-Induced Hepatokine

(2010) Jakob Hansen et al.   ENDOCRINOLOGY

A Complex Role of Activin A in Non-Alcoholic Fatty Liver Disease

(2009) Arne Yndestad et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

An Emerging Role of mTOR in Lipid Biosynthesis

(2009) Mathieu Laplante et al.   CURRENT BIOLOGY

The Follistatin-288 Isoform Alone Is Sufficient for Survival But Not for Normal Fertility in Mice

(2009) Fuminori Kimura et al.   ENDOCRINOLOGY

SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth

(2008) Thomas Porstmann et al.   Cell Metabolism